|
Market Cap (4-Jul) $407,041,472 (439th) |
Close (30-Jun) $4.40 |
Volume (30-Jun) 565,229 |
Shortsold (19-Jun) 1,217,772 (1.50%) (163rd) |
|
52w High $7.31 |
52w Low $3.74 |
P/E 285.71 |
EPS -1.56 |
MYX released this announcement to the ASX on 24 February 2023, 8:05. The announcement is not marked as price sensitive, and is 1 page(s) in length and 98.42kb in size.
You can view all announcements from MYX and see how they appear on a price chart on the announcements page.
At the date of this announcement, MYX was 4.543% short sold according to ASIC data. It was ranked the 39th most shorted stock on the ASX. It remains ranked 163rd as of the latest reported data (19 June 2025).
| Other Recent Announcements from MYX | |
|---|---|
| Notification of cessation of securities - MYX | 30 June 2023, 16:11 |
| Update - Notification of buy-back - MYX | 30 June 2023, 8:19 |
| Update - Notification of buy-back - MYX | 29 June 2023, 8:20 |
| MYX signs license & supply agreement for generic Oracea | 24 February 2023, 8:05 |
| MYX announces US launch of Diltiazem ER and Doryx MPC 60mg | 15 February 2023, 9:05 |
| Mayne Pharma to restate US dermatology net revenue for FY22 | 15 February 2023, 8:10 |
| Notification of cessation of securities - MYX | 25 January 2023, 9:58 |
You must be logged in to post a reply.
Mayne Pharma Group 